Hepatitis C virus- Biology, host evasion strategies, and promising new therapies on the horizon

被引:34
|
作者
Qureshi, Sohail A. [1 ]
机构
[1] Aga Khan Univ Hosp, Dept Biol & Biomed Sci, Karachi 74800, Pakistan
关键词
hepatitis C; hepatitis C virus (HCV); antiviral therapy; signaling pathways; evasion strategies;
D O I
10.1002/med.20063
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Hepatitis C reduces the quality of life for some 170 million people around the globe and is one of the most prevalent diseases on the planet. It is caused by the hepatitis C virus (HCV) that is replicated by an error-prone polymerase and therefore undergoes rapid evolution. To date, although much has been learned about the biology of HCV, only a partially effective combination therapy comprised of ribavirin and pegylated-interferon-alpha is available to hepatitis C sufferers. Given the prevalence of hepatitis C, together with the fact that almost half the chronically infected HCV patients are refractory to current therapy, there is an urgent need for an efficacious immuno-prophylactic that protects individuals from HCV infection, as well as drugs that impede the viral life cycle effectively and eradicate infection. Herein, I provide an overview of the molecular biology of HCV, highlighting the functions of different virally encoded proteins in terms of how they alter signaling pathways of host cell to establish an infection and discuss whether a more promising therapy for treating hepatitis C is anywhere in sight. (c) 2006 Wiley Periodicals, Inc.
引用
收藏
页码:353 / 373
页数:21
相关论文
共 50 条
  • [21] Evasion of host immune surveillance by hepatitis C virus: Potential roles in viral persistence
    Moorman, JP
    Joo, M
    Hahn, YS
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2001, 49 (03) : 189 - 194
  • [22] Hepatitis C virus therapies
    Richard E. T. Smith
    Nature Reviews Drug Discovery, 2006, 5 : 715 - 716
  • [23] Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance
    Akuta, Norio
    Suzuki, Fumitaka
    Sezaki, Hitomi
    Kobayashi, Masahiro
    Fujiyama, Shunichiro
    Kawamura, Yusuke
    Hosaka, Tetsuya
    Kobayashi, Mariko
    Saitoh, Satoshi
    Suzuki, Yoshiyuki
    Arase, Yasuji
    Ikeda, Kenji
    Kumada, Hiromitsu
    JOURNAL OF CLINICAL MICROBIOLOGY, 2019, 57 (01)
  • [24] Hepatitis C: A new horizon
    Chang, Kyong-Mi
    GASTROENTEROLOGY, 2006, 131 (06) : 1667 - 1668
  • [25] Natural killer cells: Primary target for hepatitis C virus immune evasion strategies?
    Golden-Mason, L
    Rosen, HR
    LIVER TRANSPLANTATION, 2006, 12 (03) : 363 - 372
  • [26] Hepatitis C virus biology
    Giannini, C
    Bréchot, C
    CELL DEATH AND DIFFERENTIATION, 2003, 10 (Suppl 1): : S27 - S38
  • [27] Hepatitis C virus biology
    C Giannini
    C Bréchot
    Cell Death & Differentiation, 2003, 10 : S27 - S38
  • [28] Comparing dental students' knowledge of and attitudes toward hepatitis B virus-, hepatitis C virus-, and HIV-infected patients in Taiwan
    Hu, SW
    Lai, HR
    Liao, PH
    AIDS PATIENT CARE AND STDS, 2004, 18 (10) : 587 - 593
  • [29] Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus- Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Cho, Juhee
    Paik, Seung Woon
    Yoo, Byung Chul
    PLOS ONE, 2015, 10 (01):
  • [30] Development of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-related cirrhosis
    Akarca, US
    Lebe, E
    Karasu, Z
    Gunsar, F
    Ersoz, G
    Batur, Y
    JOURNAL OF HEPATOLOGY, 2002, 36 : 76 - 76